Public Health | November 16, 2021
Biocon Biologics partners with RSSDI to expand insulin access
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%
The centre has an initial capacity of 500 FTEs
LSDCheck is CE-IVD approved LCMSMS-based testing kit for LSD in newborns
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
This strategic collaboration will enable continued innovation in cancer care
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
